ReviewiScience2026
Targeting molecular pathways in neuropathic cancer pain: from mechanisms to novel therapeutics.
Review in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Discovery of a peripherally restricted αCell reports. Medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuropathic cancer pain (NCP) remains a formidable clinical adversary, severely compromising the quality of life for cancer survivors. Its pathogenesis is highly complex and multifactorial, bifurcated into tumor-induced and chemotherapy-induced neuropathic pain. This review dissects the intricate molecular mechanism of NCP, highlighting how the tumor microenvironment orchestrates neuro-tumor interaction. Bridging the gap between pathogenesis and treatment, we evaluate the vanguard of therapeutic strategies designed to breach the current therapeutic impasse. We specifically explore the potential of antisense oligonucleotides in silencing pathological gene expression, the deployment of nanotechnology for bespoke drug delivery, the targets of neuro-tumor interactions, and the modulation of the endocannabinoid system as a novel analgesic target. In summary, by integrating pathogenic insights with therapeutic innovations, this review aims to catalyze a paradigm shift, from symptomatic management to mechanism-based precision intervention, paving the way for a new epoch in NCP management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.